---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025257"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:38:11.108071+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026

## Summary
- Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.
- Notes mature Feb 19, 2026; convertible at 80% of lowest closing price in prior 5 trading days.
- Proceeds to pay off debt and for working capital; RBW Capital Partners received 8% commission.
- Registration rights agreement requires resale registration statement filed by Sept 18, 2025.
- Company may prepay at 20% premium; conversion capped at 4.99% (or 9.99%) beneficial ownership.

## SEC filing metadata
- accession: 0001641172-25-025257
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000164117225025257/0001641172-25-025257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000164117225025257/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025257
- JSON: https://secwatch.observer/filing/0001641172-25-025257.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.